SCHEMBL1179211

SCHEMBL1179211

CC(C)(C)[Si](OCc1ccc(S(N)(=O)=O)cc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA2 P00918 18/20 0.49
CA1 P00915 16/20 0.49
CA9 Q16790 10/20 0.49
CA12 O43570 9/20 0.49
CA7 P43166 5/20 0.49
CA4 P22748 4/20 0.49
CA5A P35218 3/20 0.49
CA5B Q9Y2D0 3/20 0.49
CA14 Q9ULX7 2/20 0.44
MAPT P10636 1/20 0.42
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CA3 P07451 1/20 0.41
CA6 P23280 1/20 0.41
PLA2G7 Q13093 1/20 0.41
CA13 Q8N1Q1 1/20 0.41
SOS1 Q07889 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1314001 0.82 AGXT (0.42) MAPTSMN1; SMN2
SCHEMBL222047 0.81 MAOB (0.43) MAPTSMN1; SMN2
SCHEMBL11934179 0.79 TP53 (0.42) MAPTSMN1; SMN2
SCHEMBL9347235 0.79 ESR1 (0.43) MAPT
SCHEMBL14542685 0.79 AGXT (0.43) CA2CA1CA9MAPTKDM4E
SCHEMBL5574184 0.79 IDO1 (0.50) MAPTSMN1; SMN2
SCHEMBL1178907 0.78 ALDH1A1 (0.53) MAPTKDM4ESMN1; SMN2
SCHEMBL19475264 0.78 TDP1 (0.34) CA2CA1CA9CA12CA7
SCHEMBL9347236 0.78 AGXT (0.33) SMN1; SMN2
SCHEMBL4587307 0.78 IDO1 (0.42) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2610247-B1 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LTD (BS) 2016-05-25 EP disclosed
EP-2265589-B1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BAHAMAS LTD (BS) 2016-01-27 EP disclosed
US-9126942-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LIMITED (BS) 2015-09-08 US disclosed
US-9126942-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LIMITED (BS) 2015-09-08 US disclosed
US-20150051239-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BAHAMAS LIMITED (BS) 2015-02-19 US disclosed
US-20150051239-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BAHAMAS LIMITED (BS) 2015-02-19 US disclosed
US-8901108-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LIMITED (BS) 2014-12-02 US disclosed
US-8901108-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LIMITED (BS) 2014-12-02 US disclosed
US-20140011775-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBOTT HEALTHCARE PRODUCTS B.V. (NL) 2014-01-09 US disclosed
US-20140011775-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBOTT HEALTHCARE PRODUCTS B.V. (NL) 2014-01-09 US disclosed
US-8563723-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBOTT HEALTHCARE PRODUCTS, B.V. (NL) 2013-10-22 US disclosed
US-8563723-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBOTT HEALTHCARE PRODUCTS, B.V. (NL) 2013-10-22 US disclosed
EP-2610247-A1 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists Abbott Healthcare Products B.V. (NL) 2013-07-03 EP disclosed
US-20110046171-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBOTT HOSPITALS LIMITED (BS) 2011-02-24 US disclosed
US-20110046171-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBOTT HOSPITALS LIMITED (BS) 2011-02-24 US disclosed
EP-2265589-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS Abbott Healthcare Products B.V. (NL) 2010-12-29 EP disclosed
WO-2009115515-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS SOLVAY PHARMACEUTICALS B.V. (NL) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051239-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS HTR6, HTR2C, HTR4 CA2 4148/4885CA1 3815/4885CA9 4827/4885
US-20110046171-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS HTR6, HTR2C, HTR4 CA2 4148/4885CA1 3815/4885CA9 4827/4885
US-20140011775-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS HTR6, HTR2C, HTR4 CA2 4148/4885CA1 3815/4885CA9 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.